Weight Regain After GLP-1-Based Therapy Discontinuation: Failure, Physiology, or Follow-Up Gap.

The introduction of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual incretin agonists targeting both the GIP and GLP-1 receptors (GIP/GLP-1 dual agonists) has reshaped obesity management, approaching degrees of weight loss previously achievable largely through metabolic surgery. However, randomized withdrawal trials, including Semaglutide Treatment Effect in People with Obesity (STEP) 4 and SURMOUNT 4, show that discontinuation of GLP-1-based therapy is consistently followed by rapid weight regain (typically observed within one year of withdrawal) and a decline in cardiometabolic benefits. Rather than indicating therapeutic failure, this pattern is best understood as disease recurrence, reinforcing obesity as a chronic, relapsing condition.

After treatment is discontinued, homeostatic weight-defense mechanisms re-emerge, favoring a return toward the pre-treatment set point. This editorial examines the biology underpinning post-discontinuation weight regain and highlights a clinically underappreciated consequence: sarcopenic obesity, driven by preferential fat mass recovery relative to lean mass. It also discusses mitigation strategies, including resistance training and structured tapering approaches, and argues for long-term, maintenance-oriented care as an ethical imperative in chronic obesity management.